問卷
Log In
繁中 EN
TPIDB
TPIDB Outstanding PI
TPIDB > Principal Investigator

Principal Investigator


MacKay Memorial Hospital (在職)

Division of Endocrinology

MacKay Memorial Hospital

Division of Endocrinology

更新時間：2023-09-19

劉松臻
  • Principal Investigator
  • Clinical Trial Experience (year)

Recruiting Trial

1Cases

篩選

Developmental Phase

  • Phase I

  • Phase I/II

  • Phase II

  • Phase II/III

  • Phase III

  • Phase IV

  • Others

Trial Status

  • Not yet recruiting

  • Active

  • Completed

Recruitment Status

  • Not yet recruiting

  • Recruiting

  • Completed

  • Terminated

  • Stop recruiting

  • Suspended

  • Study ended

Trial scale

  • Multi-Regional Multi-Center

  • Taiwan Multiple Center

  • Taiwan Single Center

The expected start time interval of the test

-

Trial Applicant

  • Hospital/Foundation

  • Pharmaceutical/Biopharmaceutical company

  • Contract Research Organization

Important Roles

  • Asia Regional PI

  • Taiwan National PI

  • Chairman/Global PI

  • Steering Committee

  • Advisory board

  • None

Audit by Sponsors/CRO

  • Sponsors

  • CRO

  • None

Investigator-initiated trial(IIT)

  • Yes

Filters

劉松臻

List

6Cases

2026-05-11 - 2030-01-07

Phase III

Not yet recruiting
Efficacy and safety of NNC0487-0111 compared to placebo on morbidity and mortality in people with heart failure with preserved or mildly reduced ejection fraction and obesity (HF-POLARIS).

  • Condition/Disease

    Heart Failure, Obesity

  • Test Drug

    NNC0487-0111 B

Participate Sites
5Sites

Not yet recruiting5Sites

2025-03-01 - 2030-06-30

Active
A phase III, randomized, double-blind, placebo-controlled, event-driven trial was conducted to evaluate the effect of Baxdrostat in combination with Dapagliflozin compared to Dapagliflozin alone on the risk of first-time heart failure and cardiovascular death in participants at high risk of developing heart failure.

  • Condition/Disease

    The time elapsed before the first occurrence of any of the following events: • Hospitalization due to HF • Non-hospitalized HF • Death due to CV

  • Test Drug

    Baxdrostat Dapagliflozin

Participate Sites
18Sites

Recruiting18Sites

2005-04-01 - 2007-01-01

Phase III

Not yet recruiting

  • Condition/Disease

  • Test Drug

Participate Sites
2Sites

Terminated2Sites

2008-07-01 - 2010-04-30

Phase III

  • Condition/Disease

  • Test Drug

Participate Sites
12Sites

Terminated12Sites

2010-03-03 - 2010-12-31

Phase III

A pan-Asian clinical trial comparing the efficacy and safety of insulin NN1250 and insulin glargin in patients with type 2 diabetes who are currently using oral hypoglycemic drugs. A 26-week, randomized, confirmatory, controlled, open-ended, multi-center, multi-country, clinical trial that achieves the treatment goals, comparing SIBA and insulin glargine injected once a day with oral hypoglycemic drugs for type 2 diabetes The efficacy and safety of patients.

  • Condition/Disease

    Diabetes

  • Test Drug

    Insulin 454 (SIBA) 100 U/ml, 3 mL prefilled pen, solution for injection

Participate Sites
8Sites

Terminated8Sites

2016-05-06 - 2017-08-16

Phase III

  • Condition/Disease

  • Test Drug

Participate Sites
4Sites

Terminated4Sites

聯絡我們

台灣臨床試驗主持人資料庫 TPIDB

All Contents Copyright 2020 台灣臨床試驗主持人資料庫TPIDB